667 related articles for article (PubMed ID: 18408492)
21. Quality assurance and the drug development process: an FDA perspective.
Leonard EM
Qual Assur; 1994 Jun; 3(2):178-86. PubMed ID: 7804633
[No Abstract] [Full Text] [Related]
22. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
23. Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.
Riner A; Chan-Tack KM; Murray JS
Postgrad Med; 2009 May; 121(3):139-46. PubMed ID: 19491552
[TBL] [Abstract][Full Text] [Related]
24. From laboratory to medicine cabinet.
Caring; 1992 Nov; 11(11):16-20. PubMed ID: 10121248
[TBL] [Abstract][Full Text] [Related]
25. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
26. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
[TBL] [Abstract][Full Text] [Related]
27. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
28. New drug and antibiotic regulations--FDA. Proposed rule.
Fed Regist; 1982 Oct; 47(202):46622-66. PubMed ID: 10262075
[TBL] [Abstract][Full Text] [Related]
29. Ophthalmic drug development: procedural considerations.
Novack GD
J Glaucoma; 1998 Jun; 7(3):202-9. PubMed ID: 9627860
[No Abstract] [Full Text] [Related]
30. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
Tyner K; Sadrieh N
Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
[TBL] [Abstract][Full Text] [Related]
31. Food and drug administration approval process for dermatology drugs in the United States.
Boozalis E; Semenov YR; Kwatra SG
J Dermatolog Treat; 2018 Sep; 29(6):536-538. PubMed ID: 29304565
[TBL] [Abstract][Full Text] [Related]
32. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
Basak AK; Raw AS; Al Hakim AH; Furness S; Samaan NI; Gill DS; Patel HB; Powers RF; Yu L
Adv Drug Deliv Rev; 2007 Jan; 59(1):64-72. PubMed ID: 17196703
[TBL] [Abstract][Full Text] [Related]
33. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
34. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
35. FDA review divisions: performance levels and the impact on drug sponsors.
Milne CP; Kaitin KI
Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
[TBL] [Abstract][Full Text] [Related]
36. Combination products regulation at the FDA.
Lauritsen KJ; Nguyen T
Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
[TBL] [Abstract][Full Text] [Related]
37. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
Hirschfeld S; Ho PT; Smith M; Pazdur R
J Clin Oncol; 2003 Mar; 21(6):1066-73. PubMed ID: 12637472
[TBL] [Abstract][Full Text] [Related]
38. Utilization of electronic resources in the NDA/BLA regulatory review of bioanalytical data: perspectives from US FDA reviewers.
Au S; Yu C; Booth B
Bioanalysis; 2011 Jul; 3(13):1441-5. PubMed ID: 21728769
[TBL] [Abstract][Full Text] [Related]
39. Pediatric drug development in anesthesiology: an FDA perspective.
Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
[No Abstract] [Full Text] [Related]
40. FDA drug classification system.
Sanborn MD; Godwin HN; Pessetto JD
Am J Hosp Pharm; 1991 Dec; 48(12):2659-62. PubMed ID: 1814217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
